Prospectus

Medical technology back on track

Retrieved on: 
Wednesday, March 13, 2024

The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.

Key Points: 
  • The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.
  • “We also anticipate a big boost in growth from the increasing use of artificial intelligence in the medical technology and healthcare services industries,” Stefan Blum adds.
  • These were generally characterized by strong growth momentum in surgical procedures and an optimistic outlook for the 2024 fiscal year,” Marcel Fritsch comments.
  • Elevance, which is focused on employer-sponsored health insurance plans, reported better-than-expected profits thanks to a drop in medical costs and an increase in management’s earnings guidance for 2024.

Custodian Property Income REIT plc: Update on recommended all-share merger with abrdn Property Income Trust Limited

Retrieved on: 
Wednesday, March 13, 2024

The CREI Board notes the API portfolio weighting to industrials is only 48% (as a % of API's portfolio by income as at 31 December 2023)8.

Key Points: 
  • The CREI Board notes the API portfolio weighting to industrials is only 48% (as a % of API's portfolio by income as at 31 December 2023)8.
  • The ULR specialist investment strategy for the combined group therefore would reflect a material divergence from the current API strategy.
  • The two principal drivers of earnings per share in a property investment company are rental income and cost of debt.
  • Data for the twelve months to 18 January 2024 (being the latest practicable date prior to the Recommended Merger Announcement).

EQS-News: KPS AG successfully carries out cash capital increase

Retrieved on: 
Wednesday, March 13, 2024

Unterfoehring/Munich, 12 March 2024 – KPS AG (WKN: A1A6V4 / ISIN: DE000A1A6V48), Europe's leading consultancy for digital transformation and process optimisation in retail, has successfully completed the cash capital increase resolved on 7 March 2024.

Key Points: 
  • Unterfoehring/Munich, 12 March 2024 – KPS AG (WKN: A1A6V4 / ISIN: DE000A1A6V48), Europe's leading consultancy for digital transformation and process optimisation in retail, has successfully completed the cash capital increase resolved on 7 March 2024.
  • The capital increase was oversubscribed.
  • A total of 3,741,200 new no-par value registered shares were placed with selected investors as part of a private placement.
  • The gross issue proceeds from the capital increase thus amount to EUR 4,302,380.00.

EQS-News: STRABAG SE: entry of non-cash capital increase in the commercial register planned for 21 March 2024

Retrieved on: 
Wednesday, March 13, 2024

The entry of the ordinary non-cash capital increase is currently planned for Thursday, 21 March 2024, following expiry of the six-month waiting period in accordance with the Austrian Stock Corporation Act (AktG).

Key Points: 
  • The entry of the ordinary non-cash capital increase is currently planned for Thursday, 21 March 2024, following expiry of the six-month waiting period in accordance with the Austrian Stock Corporation Act (AktG).
  • The new shares from this capital increase are then to be issued immediately to the holders of the existing STRABAG shares with ISIN AT0000A36HH9 (STRABAG SE – Distribution Share-Based Option).
  • The ongoing capital measures were unanimously approved at the 19th Annual General Meeting of STRABAG SE on 16 June 2023.
  • The ordinary non-cash capital increase represents the final step of these capital measures.

EQS-News: ELARIS AG plans initial listing in the m:access of the Munich Stock Exchange on 14 March 2024

Retrieved on: 
Wednesday, March 13, 2024

The securities prospectus alone contains the information for investors required by law.

Key Points: 
  • The securities prospectus alone contains the information for investors required by law.
  • It should be noted that approval of the prospectus by BaFin should not be understood as an endorsement of the securities concerned.
  • Forward-looking statements are based on current assumptions and estimates that are made by the company to the best of its knowledge.
  • 07.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

OSSIAM STOXX EUROPE 600 ESG EQUAL WEIGHT NR: change of dealing deadline

Retrieved on: 
Wednesday, March 13, 2024

The board of directors of the Company (the “Board”) would like to inform you that an amendment has been made to the prospectus of the Company (the “Prospectus”) in relation to the following sub-fund, such amendment to take effect as from 29 March 2024 (the “Effective Date”):

Key Points: 
  • The board of directors of the Company (the “Board”) would like to inform you that an amendment has been made to the prospectus of the Company (the “Prospectus”) in relation to the following sub-fund, such amendment to take effect as from 29 March 2024 (the “Effective Date”):
    Please find below a table setting out the current Dealing Deadline and the updated Dealing Deadline:
    Copies of the Prospectus and the relevant key information document (KID) reflecting the above change will be available free of charge at the registered office of the Company, once available.
  • Should you disagree with the planned change mentioned above, you may redeem your shares, free of redemption charge until 28 March 2024 in accordance with the redemption procedure set out in the Prospectus.
  • On behalf of the Company,
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.

Metabolica Health Completes Amalgamation with Big Fish and Announces Non-Brokered Private Placement

Retrieved on: 
Monday, February 26, 2024

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ("Metabolica" or the "Company") a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the "Amalgamation Agreement") with Big Fish Acquisition Corp. ("Big Fish"), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ("Metabolica Health"), continuing the business of Metabolica.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ("Metabolica" or the "Company") a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the "Amalgamation Agreement") with Big Fish Acquisition Corp. ("Big Fish"), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ("Metabolica Health"), continuing the business of Metabolica.
  • Pursuant to the terms of the Amalgamation Agreement dated October 30, 2023, Big Fish amalgamated with Metabolica to form Metabolica Health, and the issued shares of each of Metabolica and Big Fish were exchanged for shares of Metabolica Health or otherwise dealt with as follows: (a) each Class A Common share of Metabolica was exchanged for 22.213 common shares of Metabolica Health; and (b) each common share of Big Fish was exchanged for one-half of one common share of Metabolica Health.
  • Following the successful amalgamation transaction (the "Transaction"), Metabolica Health is pleased to announce that it is arranging a non-brokered private placement (the "Offering") of up to 2,500,000 Units, at a price of $0.40 per Unit, for gross proceeds of up to $1,000,000.
  • Furthermore, Metabolica Health is announcing the appointment of Mr. Scott Jardin, CPA, CGA, as the company's Chief Financial Officer.

Lucas GC Limited (NASDAQ: LGCL) Successfully Listed on NASDAQ With Appealing Valuation of the "AI+PaaS" Theme

Retrieved on: 
Wednesday, March 6, 2024

Lucas' achievements are rarely seen among the recently listed companies on NASDAQ.

Key Points: 
  • Lucas' achievements are rarely seen among the recently listed companies on NASDAQ.
  • 51Job which is 30% owned by Recruit Holding of Japan, is the second largest shareholder of Lucas which demonstrates its endorsement of Lucas' business model and roadmaps.
  • For other strategic investors, the involvement of domestic AI unicorn BeagleData serves as a notable validation of the Company's AI technology.
  • Haier Group's investment brings forth a range of enhancements to the company's corporate governance and extends multidimensional industry resource supports to Lucas.

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

Retrieved on: 
Tuesday, March 12, 2024

PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock.

Key Points: 
  • PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock.
  • Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions.
  • The Company expects to close the offering on March 14, 2024, subject to the satisfaction of customary closing conditions.
  • Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the offering.

Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million

Retrieved on: 
Monday, March 11, 2024

VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million.

Key Points: 
  • NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
    VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million.
  • The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.
  • Closing of the Offering will be subject to a number of customary conditions, including the entering into of the Underwriting Agreement and approval of the Toronto Stock Exchange.
  • The Offering will be made in Canada only by means of the base shelf prospectus and prospectus supplement.